This application aims to facilitate research on eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), and eosinophilic colitis (EC) through the development of a Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). CEGIR comprises clinical centers in Ohio (the coordinating center), Colorado, California, Indiana, Pennsylvania, Illinois, North Carolina, Massachusetts, Switzerland, and Maryland. All participating domestic, non-National Institutes of Health (NIH) clinical centers are associated with a Clinical Translational Science Award (CTSA). The CEGIR sites have been carefully chosen on the basis of their preexisting record of collaboration with each other;diverse expertise in relevant clinical specialties including Gastroenterology, Allergy, Immunology, and Pathology;the ability to integrate pediatric and adult patients into a common consortium;and well-established record of excellence in clinical research involving this patient population. Importantly, the CEGIR sites have proven access to an adequate number of patients with the rare diseases studied, as evidenced from the recent completion of the first set of controlled clinical trials involving this patient population. Strong patient advocacy groups (PAGs), including the American Partnership for Eosinophilic Disorders (APFED) and the Campaign Urging Research for Eosinophilic Disease (CURED), already partner with the CEGIR Investigators and will continue to work synergistically in the context of CEGIR. Despite the recent record of advances by CEGIR Investigators, the early success of their collaborative interactions, the proactive PAGs, and the development of novel anti-eosinophil therapeutics, there is no currently existing funding for a clinical network focusing on these three rare, distinct diseases, highlightig the timeliness and importance of this application.

Public Health Relevance

Eosinophilic esophagitis, eosinophilic gastritis, and eosinophilic colitis are painful, lifelong diseases that make it difficult or impossible for indiviuals to eat many or all foods. Individuals with these diseases often have to fuel their bodies by drinking costly formulas. We will partner with researchers, patients, and other key groups, including patient advocacy groups, to better understand, treat, and educate about these diseases.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZTR1-CI-8 (01))
Program Officer
Minnicozzi, Michael
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Cincinnati Children's Hospital Medical Center
United States
Zip Code
Patel, Ronak Vashi; Hirano, Ikuo (2018) New Developments in the Diagnosis, Therapy, and Monitoring of Eosinophilic Esophagitis. Curr Treat Options Gastroenterol 16:15-26
Jensen, Elizabeth T; Dellon, Evan S (2018) Environmental factors and eosinophilic esophagitis. J Allergy Clin Immunol 142:32-40
Egan, Maureen; Atkins, Dan (2018) What Is the Relationship Between Eosinophilic Esophagitis (EoE) and Aeroallergens? Implications for Allergen Immunotherapy. Curr Allergy Asthma Rep 18:43
Khoury, Paneez; Akuthota, Praveen; Ackerman, Steven J et al. (2018) Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD). J Leukoc Biol 104:69-83
Whelan, Kelly A; Muir, Amanda B; Nakagawa, Hiroshi (2018) Esophageal 3D Culture Systems as Modeling Tools in Esophageal Epithelial Pathobiology and Personalized Medicine. Cell Mol Gastroenterol Hepatol 5:461-478
Zevit, Noam; Furuta, Glenn T (2018) Eosinophilic Gastroenteritis and Colitis: Not Yet Ready for the Big Leagues. J Pediatr Gastroenterol Nutr 67:1-2
Durrani, Sandy R; Mukkada, Vincent A; Guilbert, Theresa W (2018) Eosinophilic Esophagitis: an Important Comorbid Condition of Asthma? Clin Rev Allergy Immunol 55:56-64
Rochman, Mark; Azouz, Nurit P; Rothenberg, Marc E (2018) Epithelial origin of eosinophilic esophagitis. J Allergy Clin Immunol 142:10-23
Philpott, Hamish; Dellon, Evan (2018) Histologic improvement after 6 weeks of dietary elimination for eosinophilic esophagitis may be insufficient to determine efficacy. Asia Pac Allergy 8:e20
Fahey, Lisa M; Chandramouleeswaran, Prasanna M; Guan, Shaobo et al. (2018) Food allergen triggers are increased in children with the TSLP risk allele and eosinophilic esophagitis. Clin Transl Gastroenterol 9:139

Showing the most recent 10 out of 103 publications